FOCUS ON: TYPE 2 DIABETES IN THE ELDERLY & FRAIL

Type 2 diabetes management in the elderly and frail

Of all type 2 diabetes patients, polypharmacy is most prevalent in the elderly,¹ which has been found to negatively impact health outcomes² and quality of life.^1,3

Healthcare professionals can help to reduce treatment burden and improve health-related quality of life in this complex patient group, by individualising treatment plans.⁴

Click here to find out more

Focus on: Type 2 diabetes in the elderly & frail

Proven efficacy vs placebo^5,6

Proven efficacy vs placebo^5,6: The efficacy and safety of 5 mg linagliptin was evaluated in eight phase III randomised controlled trials.^* Linagliptin once daily demonstrated clinically significant improvements in glycaemic control vs placebo or comparator.⁵

Demonstrated CV and kidney safety profile

Long-term cardiovascular and kidney safety profile of Trajenta® has been demonstrated in two cardiovascular outcome trials.^7-12 As Trajenta® is primarily excreted via the bile, it is suitable for a broad range of adults with type 2 diabetes independent of renal function.⁵

TRAJENTA® (linagliptin) dose and administration

Unique convenience of one dose, once daily⁵

The recommended dose of Trajenta® for adult patients with type 2 diabetes is 5 mg once daily, independent of renal and hepatic^# function, body mass index, age, ethnicity, background type 2 diabetes therapy^† and disease duration.^5,13

Know more

Know more

Know more

Know more

Abbreviation:

CV: cardiovascular

Footnotes

§
Treatment difference of 0.8% in favour of linagliptin for adjusted mean HbA1c reduction at 24-weeks between linagliptin and placebo groups.
*
CARMELINA® included 6,979 patients with albuminuria & previous macrovascular disease, and/or impaired kidney function with or without CV comorbidities. CAROLINA® included 6,033 patients with one or more of the following: a) previous vascular disease, b) evidence of vascular- related end-organ damage, c) age: ≥ 70 years and d) ≥ 2 CV risk factors (smoking, hypertension, T2D duration ≥ 10 years, dyslipidemia).
#
Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking.
†
Sulphonylureas and insulin are known to cause hypoglycaemia. Therefore, caution is advised when linagliptin is used in combination with a sulphonylurea and/or insulin. A dose reduction of the sulphonylurea or insulin may be considered.

References:

Austin R P. Diabetes Spectr. 2006;19(1):13–16.
Boateng I, et al. PLoS One. 2025;20(2):e0317907.
Schenker Y, et al. J Gen Intern Med. 2019;34(4):559–566.
Huang E S. JAMA Intern Med. 2024;184(4):435–436.
Trajenta (linagliptin) Summary of Product Characteristics (SmPC). Available at EMC.
Del Prato S, et al. J Diab Compl. 2013;27:274–279.
Rosenstock J, et al. Cardiovasc Diabetol. 2018;17:39.
Rosenstock J, et al. JAMA. 2019;321:69–79.
Cooper M, et al. Diabetes Obes Metab. 2020;22:1062–73.
Marx N, et al. Diab Vasc Res. 2015;12:164–74.
Rosenstock J, et al. JAMA. 2019;322:1155–66.
Espeland MA, et al. Diabetes Obes Metab. 2021;23:569–80.
Lajara R, et al. Clin Ther. 2014;36:1595–605.

PC-GB-110486 V3 | July 2025

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:

monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.